Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...
Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback